Last reviewed · How we verify
Xibrom, and Optive
Xibrom, and Optive is a Topical NSAID (Xibrom); Artificial tear/lubricant (Optive) Small molecule drug developed by Bp Consulting, Inc. It is currently FDA-approved for Postoperative ocular inflammation and pain following cataract surgery (Xibrom), Dry eye disease/ocular surface disease (Optive).
Xibrom is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain in the eye, while Optive is a lubricating eye drop that provides ocular surface hydration.
Xibrom is a small molecule used in the treatment of cataracts, as indicated by ClinicalTrials.gov. Optive is also used in the treatment of cataracts, as shown by ClinicalTrials.gov, although its mechanism is not specified.
At a glance
| Generic name | Xibrom, and Optive |
|---|---|
| Sponsor | Bp Consulting, Inc |
| Drug class | Topical NSAID (Xibrom); Artificial tear/lubricant (Optive) |
| Target | COX-1/COX-2 (Xibrom); None—lubricant formulation (Optive) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Xibrom (bromfenac) works by blocking COX-1 and COX-2 enzymes, thereby reducing prostaglandin synthesis and decreasing ocular inflammation, pain, and photophobia. Optive is a preservative-free artificial tear formulation containing carboxymethylcellulose and glycerin that lubricates and protects the ocular surface, addressing dry eye symptoms through mechanical hydration rather than anti-inflammatory action.
Approved indications
- Postoperative ocular inflammation and pain following cataract surgery (Xibrom)
- Dry eye disease/ocular surface disease (Optive)
Common side effects
- Ocular irritation or stinging (Xibrom)
- Transient blurred vision (Xibrom)
- Mild ocular discomfort (Optive)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xibrom, and Optive CI brief — competitive landscape report
- Xibrom, and Optive updates RSS · CI watch RSS
- Bp Consulting, Inc portfolio CI
Frequently asked questions about Xibrom, and Optive
What is Xibrom, and Optive?
How does Xibrom, and Optive work?
What is Xibrom, and Optive used for?
Who makes Xibrom, and Optive?
What drug class is Xibrom, and Optive in?
What development phase is Xibrom, and Optive in?
What are the side effects of Xibrom, and Optive?
What does Xibrom, and Optive target?
Related
- Drug class: All Topical NSAID (Xibrom); Artificial tear/lubricant (Optive) drugs
- Target: All drugs targeting COX-1/COX-2 (Xibrom); None—lubricant formulation (Optive)
- Manufacturer: Bp Consulting, Inc — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Postoperative ocular inflammation and pain following cataract surgery (Xibrom)
- Indication: Drugs for Dry eye disease/ocular surface disease (Optive)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing